Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the a...

Bibliográfalaš dieđut
Váldodahkkit:	Mease, P, Kavanaugh, A, Coates, L, McInnes, I, Hojnik, M, Zhang, Y, Anderson, J, Dorr, A, Gladman, D
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	BMJ Publishing Group 2017

Geahča maid

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2019)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
Dahkki: Kavanaugh, A, et al.
Almmustuhtton: (2024)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
Dahkki: Gladman, DD, et al.
Almmustuhtton: (2018)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
Dahkki: Mease, PJ, et al.
Almmustuhtton: (2020)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
Dahkki: Choy, E, et al.
Almmustuhtton: (2007)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
Dahkki: Coates, LC, et al.
Almmustuhtton: (2021)

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
Dahkki: Kavanaugh, A, et al.
Almmustuhtton: (2005)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Dahkki: Coates, LC, et al.
Almmustuhtton: (2024)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
Dahkki: Landewé, R, et al.
Almmustuhtton: (2019)

Psoriatic arthritis
Dahkki: FitzGerald, O, et al.
Almmustuhtton: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2023)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
Dahkki: Désirée van der Heijde, et al.
Almmustuhtton: (2020-02-01)

Classification and outcome measures for psoriatic arthritis
Dahkki: Leung, Y, et al.
Almmustuhtton: (2018)

Measuring outcomes in psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2020)

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Dahkki: Laura C. Coates, et al.
Almmustuhtton: (2024-02-01)

Considerations for the definition of remission criteria in psoriatic arthritis
Dahkki: Mease, P, et al.
Almmustuhtton: (2017)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
Dahkki: Orbai, A-M, et al.
Almmustuhtton: (2019)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
Dahkki: Alexis Ogdie, et al.
Almmustuhtton: (2023-05-01)

Assessing disease activity in psoriatic arthritis: a literature review
Dahkki: Tucker, L, et al.
Almmustuhtton: (2018)

Classification and Outcome Measures for Psoriatic Arthritis
Dahkki: Ying Ying Leung, et al.
Almmustuhtton: (2018-09-01)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
Dahkki: Soriano, ER, et al.
Almmustuhtton: (2023)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

Residual inflammation in psoriatic arthritis patients in stable minimal disease activity
Dahkki: Pierluigi Macchioni, et al.
Almmustuhtton: (2022-12-01)

Methotrexate in psoriasis and psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2020)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Dahkki: Helliwell, PS, et al.
Almmustuhtton: (2022)

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
Dahkki: Ye, W, et al.
Almmustuhtton: (2018)

Sustained very low disease activity and remission in psoriatic arthritis patients
Dahkki: Lubrano, E, et al.
Almmustuhtton: (2019)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
Dahkki: Yazji, SM, et al.
Almmustuhtton: (2025)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
Dahkki: Strand, V, et al.
Almmustuhtton: (2022)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Dahkki: Ennio Lubrano, et al.
Almmustuhtton: (2019-08-01)

Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
Dahkki: Silvia Scriffignano, et al.
Almmustuhtton: (2023-09-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
Dahkki: Coates, L, et al.
Almmustuhtton: (2021)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
Dahkki: Coates, L, et al.
Almmustuhtton: (2018)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
Dahkki: Mease, PJ, et al.
Almmustuhtton: (2019)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
Dahkki: Atul Deodhar, et al.
Almmustuhtton: (2022-07-01)

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
Dahkki: Coates, L, et al.
Almmustuhtton: (2018)

Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study
Dahkki: Rubén Queiro, et al.
Almmustuhtton: (2017-03-01)

BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS
Dahkki: D.D. Gladman
Almmustuhtton: (2011-09-01)

Duration of Psoriatic Skin Disease as Risk Factor for Subsequent Onset of Psoriatic Arthritis
Dahkki: Alexander Egeberg, et al.
Almmustuhtton: (2018-03-01)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
Dahkki: Laura C. Coates, et al.
Almmustuhtton: (2018-08-01)